Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.

Item
http://www.wikidata.org/entity/Q33366370
p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problemsBevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancerA binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Abdominopelvic washings: A comprehensive review.Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia.Wnt5A regulates the expression of ROR2 tyrosine kinase receptor in ovarian cancer cells.Low-grade serous carcinoma of the ovary or peritoneum.Molecular characterization of 103 ovarian serous and mucinous tumors.
P2860

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.

Item
http://www.wikidata.org/entity/Q33366370
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Subdividing ovarian and perito ...... in vitro drug resistance data.
@ast
Subdividing ovarian and perito ...... in vitro drug resistance data.
@en
type
label
Subdividing ovarian and perito ...... in vitro drug resistance data.
@ast
Subdividing ovarian and perito ...... in vitro drug resistance data.
@en
prefLabel
Subdividing ovarian and perito ...... in vitro drug resistance data.
@ast
Subdividing ovarian and perito ...... in vitro drug resistance data.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Subdividing ovarian and perito ...... in vitro drug resistance data.
@en
P2093
P304
P31
P356
10.1097/PAS.0B013E31816FD555
P407
P433
P478
P50
P577
P698